NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company’s initial public offering conducted between February 9 and 13, 2024 (the “IPO”), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

SAN DIEGO, Oct. 29, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a deadline is coming up on November 25th in the lawsuit that was filed for certain investors in Metagenomi, Inc. (NASDAQ: MGX) shares. Investors who suffered losses in excess of $100,000 with shares of Metagenomi, Inc. (NASDAQ: MGX) have certain options and there are short and strict deadlines running. Deadline: November 25, 2024. Metagenomi, Inc. (NASDAQ: MGX investors should contact the Shareholders Foundation at [em ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=109668&from=3 CLASS PERIOD: This lawsuit is on ...

NEW YORK, Oct. 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=109394&from=4 CLASS PERIOD: This lawsuit is on beha ...

Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated highly specific on-target deamination with no detectable translocations and no significant genomic composition differences ABE triplex editing had no adverse effects on cell viability, expansion, or other measures of cell health EMERYVILLE, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a preci ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=109175&from=3 CLASS PERIOD: This lawsuit is on ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Metagenomi, Inc. due to alleged violations of federal securities laws related to misleading statements about its collaboration with Moderna, which has led to significant investor losses [1][2]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Metagenomi between February 9, 2024, and September 26, 2024, to discuss their legal options [1]. - A federal securities class action has been filed against Metagenomi, with a deadline of November 25, 2024, for investors to seek the role of lead plaintiff [1][4]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [1]. Group 2: Allegations Against Metagenomi - The complaint alleges that Metagenomi and its executives made false and misleading statements regarding their collaboration with Moderna, which was a key aspect of their business model [2]. - Metagenomi's initial public offering took place on February 13, 2024, selling 6.25 million shares at $15 per share [3]. - The collaboration with Moderna was terminated on May 1, 2024, leading to a significant drop in Metagenomi's stock price from $7.04 to $6.17 per share within a day [3]. Group 3: Investor Participation and Information - The lead plaintiff in the class action is defined as the investor with the largest financial interest who is typical of class members [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Metagenomi's conduct [4].

NEW YORK, Oct. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company's initial public offering conducted between February 9 and 13, 2024 (the "IPO"), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

PHILADELPHIA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Metagenomi Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX). The lawsuit has been filed on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the "Class Period"). CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT. Investors who purchased or acquired METAGENOMI securities during the Class Period may, no later than NOVEMBER 25, 2024, seek to be appointed a ...

Lawsuit Overview - A class action lawsuit has been filed against Metagenomi Inc on behalf of investors who acquired its securities between February 9 2024 and May 1 2024 [1] - Investors have until November 25 2024 to apply to be appointed as lead plaintiff in the lawsuit [1] IPO and Stock Performance - Metagenomi conducted its IPO on February 12 2024 selling approximately 6 25 million shares at $15 per share [1] - On May 1 2024 Metagenomi announced the termination of its collaboration with Moderna leading to a 12 4% decline in share price from $7 04 to $6 17 [1] Allegations in the Lawsuit - The lawsuit alleges that Metagenomi's IPO registration statements were false and/or materially misleading [2] - Metagenomi represented itself as having a long-standing business relationship with Moderna but the collaboration was terminated shortly after the IPO [2] Law Firm Information - Kirby McInerney LLP is handling the lawsuit and has a history of recovering billions of dollars for shareholders in securities litigation [3]